Levonantradol for the treatment of chemotherapy-induced nausea and vomiting.
Twenty patients with cancer previously unresponsive to antiemetic treatment of chemotherapy-induced nausea and vomiting were treated with the new tetrahydrocannabinoid Levonantradol. 15 patients experienced substantial relief and 10 of them preferred the drug for further courses. These observations suggest that Levonantradol can be beneficial to patients refractory to conventional antiemetic therapy.
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001007:Anxiety / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004244:Dizziness / Q000139:chemically induced; D005260:Female; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D010617:Phenanthridines / Q000009:adverse effects / Q000627:therapeutic use*; D013237:Stereoisomerism; D014717:Vertigo / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000970:Antineoplastic Agents; D010617:Phenanthridines; C025490:nantradol